Samsung Biologics Co Ltd, founded in 2011 and headquartered in Incheon, South Korea, is a leading biopharmaceutical company dedicated to providing high-quality contract development and manufacturing services (CDMO) for biopharmaceutical products. The company specializes in the manufacturing of monoclonal antibodies and recombinant proteins and is recognized for its state-of-the-art facilities and advanced technology in the bioprocessing sector.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| SAMBIO 2.19% 2026-09-03 KRWSamsung Biologics Co Ltd | South Korea | 2026-09-03 | 2.194 | 2.74 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
As of recent data, Samsung Biologics has made significant strides in the bond markets, first issuing corporate bonds in 2014 to fund its expansion and operational capabilities. Notable bond offerings include a ₩1.8 trillion issuance in 2020, which was among the largest for a biotech firm in South Korea. Currently, their bonds exhibit yields competitive with industry averages, reflecting strong investor confidence. In June 2023, they announced a bond buyback, signaling positive cash flow and solidified financial health.